JO3327B1 - تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن - Google Patents

تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن

Info

Publication number
JO3327B1
JO3327B1 JOP/2010/0317A JOP20100317A JO3327B1 JO 3327 B1 JO3327 B1 JO 3327B1 JO P20100317 A JOP20100317 A JO P20100317A JO 3327 B1 JO3327 B1 JO 3327B1
Authority
JO
Jordan
Prior art keywords
cyano
hydroxy
enoic acid
trifluormethylphenyl
improved stability
Prior art date
Application number
JOP/2010/0317A
Other languages
English (en)
Inventor
Gerrit Hauck Dr
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3327(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of JO3327B1 publication Critical patent/JO3327B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق هذا الاختراع بتركيبات صيدلية صلبة تتضمن (Z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد، بالاضافة إلى طريقة لتحضير هذا المركب، وطرق إستخدام تلك التركيبات لعلاج الاشخاص الذين يعانون من أمراض المناعة الذاتية وعلى وجه الخصوص الذئبة الحمراء أو الامراض المزمنة التي تحدث بسبب تفاعلات العضو المزروع بداخل العائل، التصلب المتعدد أو الالتهاب الروماتيزمي للمفاصل.
JOP/2010/0317A 2009-09-18 2010-09-16 تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن JO3327B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18

Publications (1)

Publication Number Publication Date
JO3327B1 true JO3327B1 (ar) 2019-03-13

Family

ID=41510564

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0317A JO3327B1 (ar) 2009-09-18 2010-09-16 تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن

Country Status (40)

Country Link
US (5) US20120172427A1 (ar)
EP (1) EP2477611B1 (ar)
JP (1) JP2013505213A (ar)
KR (1) KR101547880B1 (ar)
CN (4) CN104666238B (ar)
AR (1) AR078383A1 (ar)
AU (2) AU2010297357B2 (ar)
BR (1) BR112012006184B1 (ar)
CA (1) CA2772275A1 (ar)
CL (1) CL2015000047A1 (ar)
CO (1) CO6511244A2 (ar)
CR (2) CR20170078A (ar)
CY (1) CY1119364T1 (ar)
DK (1) DK2477611T3 (ar)
DO (1) DOP2012000070A (ar)
ES (1) ES2625731T3 (ar)
GT (1) GT201200075A (ar)
HK (2) HK1206245A1 (ar)
HN (1) HN2012000576A (ar)
HR (1) HRP20170904T1 (ar)
HU (1) HUE032963T2 (ar)
IL (3) IL218492A (ar)
JO (1) JO3327B1 (ar)
LT (1) LT2477611T (ar)
MA (1) MA33585B1 (ar)
ME (1) ME02765B (ar)
MX (1) MX336663B (ar)
MY (1) MY155613A (ar)
NZ (2) NZ598744A (ar)
PE (2) PE20121478A1 (ar)
PL (1) PL2477611T3 (ar)
PT (1) PT2477611T (ar)
RS (1) RS56074B1 (ar)
RU (2) RU2012115459A (ar)
SI (1) SI2477611T1 (ar)
TN (1) TN2012000061A1 (ar)
TW (2) TWI468190B (ar)
UA (2) UA107582C2 (ar)
UY (1) UY32889A (ar)
WO (1) WO2011032929A1 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336663B (es) * 2009-09-18 2016-01-27 Sanofi Sa Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
AU2014352920A1 (en) * 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016189406A1 (en) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
CN114765954B (zh) * 2019-07-17 2024-01-02 赛特凯恩蒂克公司 心脏肌节抑制剂口服制剂
WO2022085015A1 (en) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited A solid oral composition of teriflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DK0787491T3 (da) 1994-10-17 2000-10-16 Aventis Pharma Ltd Middel til forebyggelse og behandling af allergiske sygdomme af type I
DE59801792D1 (de) 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001060363A1 (en) 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
ATE396719T1 (de) 2001-04-05 2008-06-15 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
SG142305A1 (en) * 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
PT1810676E (pt) 2006-01-24 2009-01-02 Teva Pharma Formulações de levetiracetam e métodos para a sua preparação
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en) 2007-05-08 2009-05-06 Ulrike Wiebelitz Therapy of benign prostatic hyperplasia (bph)
MX336663B (es) * 2009-09-18 2016-01-27 Sanofi Sa Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Also Published As

Publication number Publication date
CA2772275A1 (en) 2011-03-24
DOP2012000070A (es) 2012-05-31
PE20152031A1 (es) 2016-01-14
KR101547880B1 (ko) 2015-08-27
US20140235888A1 (en) 2014-08-21
CN104666238A (zh) 2015-06-03
US20120172427A1 (en) 2012-07-05
CR20120116A (es) 2012-06-15
IL264912B (en) 2019-11-28
HK1206245A1 (en) 2016-01-08
TWI468190B (zh) 2015-01-11
NZ617025A (en) 2014-03-28
US20190241505A1 (en) 2019-08-08
TW201117838A (en) 2011-06-01
HUE032963T2 (en) 2017-11-28
MX336663B (es) 2016-01-27
RU2012115459A (ru) 2013-10-27
ES2625731T3 (es) 2017-07-20
IL218492A0 (en) 2012-04-30
CL2015000047A1 (es) 2015-06-12
TN2012000061A1 (en) 2013-09-19
UA107582C2 (uk) 2015-01-26
US20170247319A1 (en) 2017-08-31
EP2477611A1 (en) 2012-07-25
CN102596184B (zh) 2015-03-11
EP2477611B1 (en) 2017-04-05
AR078383A1 (es) 2011-11-02
HK1206244A1 (en) 2016-01-08
US8802735B2 (en) 2014-08-12
NZ598744A (en) 2013-11-29
SI2477611T1 (sl) 2017-07-31
MX2012003122A (es) 2012-04-10
CN102596184A (zh) 2012-07-18
GT201200075A (es) 2014-05-14
RS56074B1 (sr) 2017-10-31
UA115979C2 (uk) 2018-01-25
CY1119364T1 (el) 2018-02-14
AU2013257516B2 (en) 2015-09-17
US20120208880A1 (en) 2012-08-16
JP2013505213A (ja) 2013-02-14
ME02765B (me) 2018-01-20
DK2477611T3 (en) 2017-07-10
MY155613A (en) 2015-11-13
RU2015151938A3 (ar) 2019-01-15
PL2477611T3 (pl) 2017-09-29
CN104666238B (zh) 2018-04-06
WO2011032929A1 (en) 2011-03-24
BR112012006184A2 (pt) 2016-05-31
AU2010297357A1 (en) 2012-04-05
UY32889A (es) 2011-04-29
CR20170078A (es) 2017-05-22
IL244809B (en) 2019-03-31
TWI522130B (zh) 2016-02-21
CN104739821A (zh) 2015-07-01
LT2477611T (lt) 2017-06-26
CN104739821B (zh) 2018-04-06
RU2681079C2 (ru) 2019-03-04
PE20121478A1 (es) 2012-11-12
HRP20170904T1 (hr) 2017-09-08
TW201517935A (zh) 2015-05-16
HN2012000576A (es) 2015-01-26
AU2010297357B2 (en) 2013-11-07
CN104666272A (zh) 2015-06-03
RU2015151938A (ru) 2019-01-15
IL244809A0 (en) 2016-04-21
IL218492A (en) 2016-04-21
PT2477611T (pt) 2017-06-05
MA33585B1 (fr) 2012-09-01
CO6511244A2 (es) 2012-08-31
BR112012006184B1 (pt) 2022-10-18
KR20120089461A (ko) 2012-08-10

Similar Documents

Publication Publication Date Title
JO3327B1 (ar) تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن
NZ606587A (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX352614B (es) Nuevos agentes anti-inflamatorios.
MX2019007708A (es) Nuevos agentes anti-inflamatorios.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
WO2012048129A3 (en) Inhibitors of polo-like kinase
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MX345245B (es) Polipeptidos manipulados que tienen duracion de accion incrementada.
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
MY164755A (en) Antagonist anti-il-7 receptor antibodies and methods
MX2013001677A (es) Formulaciones estables de linaclotida.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX2009007784A (es) Composiciones de tiacumicinas estables.
MY151005A (en) Amide compounds as boosters of antivirals
EP2590652A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VANOXERIN
DE602007007934D1 (en) Imidazoazephinonverbindungen
MXPA04009698A (es) Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
WO2008100622A3 (en) Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2009124252A3 (en) Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
WO2009043577A3 (de) 19-nor-progesterone zur kontrazeption
NI201200041A (es) Formulaciones en comprimido de la (4' - trifluorometilfenil) amida del ácido (z) - 2 - ciano - 3 - hidroxibut - 2 - enoico con estabilidad mejorada
WO2011076421A3 (en) Compositions comprising venlafaxine and celecoxib in the treatment of pain